Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jul 23;1864(11):1669–1680. doi: 10.1016/j.bbalip.2019.07.009

Figure 7.

Figure 7.

A. Plasma 12-HETE levels in as the major 12/15-LO metabolite in rodents in the presence of exogenous DHA as a substrate during LPS-induced acute inflammation. B. Plasma lipid profile of detectable anti-inflammatory 12/15-LO by-product in the presence of exogenous DHA as a substrate during LPS-induced acute inflammation. Although DHA treatment did not significantly lower plasma 12-HETE levels, it significantly restored the decrease in plasma RvD2 levels in LPS injected WT mice (n=4, *P<0.05 vs. control and #P<0.05 vs. LPS group). C. Representative images (200X) for H & E staining of the kidney sections in control WT mice, LPS injected WT mice, LPS injected WT mice plus DHA treatment, LPS injected WT mice plus RvD2 treatment, control 12/15-LO KO, LPS injected 12,15-LO KO and LPS injected 12/15-LO KO plus DHA treatment (n=4). RvD2 treatment or DHA as well as genetic inhibition of 12/15-LO reduced renal histopathological changes induced by LPS injection.